ECKERT & ZIEGLER BG 
By Seneffe, Belgium, January 4, 2012. Effective as of 1 January 2012 Abel Luzuriaga will be appointed as Managing Director of Eckert & Ziegler BEBIG and to the Board of Directors of the company. Together with Dr. Edgar Löffler the previous Vice President Sales will be responsible for the daily business. He thus replaces Dr. Gunnar Mann who will dedicate himself to other tasks in the Eckert & Ziegler Group in future. A host of further restructurings are associated with the change in the management board of Eckert & Ziegler BEBIG of which the Board of Directors promises a greater power of impact for the company.
"With Mr Luzuriaga a distinguished practical expert will move into top management, who can refer to a career of more than 20years in sales and to successes as Managing Director in the industry", Dr. Andreas Eckert, Chairman of the Supervisory Board, explained. "We are pleased that we were able to win him for this task. With his international experience he will help us to develop new markets in particular in the emerging markets."
Before his start at Eckert & Ziegler BEBIG in January 2011 as Head of Sales for France, Italy, Spain, Great Britain and India Luzuriaga worked as Managing Director at Theranostic Medizintechnik GmbH, the German branch of the Dutch brachytherapy specialist Nucletron B.V. for more than ten years. From 2007 he moreover bore the responsibility as Head of Sales for the economic area of Europe, the Middle East and Africa at Nucletron.
He started his professional career at Asea Brown Boveri AG (Mannheim) as commissioning engineer; he subsequently held leading positions in international sales in several companies (Dainippon Screen GmbH, OTESA Siemens Ecuador).
"I am very excited to take over the responsibility as Managing Director of Eckert & Ziegler BEBIG as it continues to grow into one of the global leaders in offering complete solutions in the brachytherapy", said Abel Luzuriaga. "I look forward, with the support of its strong team and its innovative product development, to expanding and driving its engagement with the worldwide radiation oncology society."
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB).
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email: ir@bebig.eu:
mailto:ir@bebig.eu
Website: www.bebig.eu:
http://www.bebig.eu/
Karolin Riehle
Investor Relations
Tel.: +49 30 94 10 84-0
Email: info@ezag.de
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
